N 2 (199) 2026. P. 36–42

INFLAMMATORY MARKERS IN PATIENTS WITH DECOMPENSATED TYPE 2 DIABETES MELLITUS AND ACUTE CORONAVIRUS INFECTION

V. I. Velychko, Ye. I. Yurchenko, D. H. Havrychenko, S. S. Shcherbakov,
I. V. Yurchenko

Odesa National Medical University, Odesa, Ukraine
Medical House Odrex, Odesa, Ukraine

DOI 10.32782/2226-2008-2026-2-5

Type 2 diabetes mellitus (T2DM) was found to be one of the main comorbidities in patients with COVID-19. However, there is a lack of studies regarding the relationship between glycated hemoglobin (HbA1c) levels, inflammatory markers, elevated body mass index (BMI) and disease severity in patients with T2DM and COVID-19.

The aim of the study was to analyze inflammatory markers in patients with decompensated type 2 diabetes mellitus who were hospitalized with acute coronavirus infection.

Materials and Methods. A retrospective study of 103 hospitalized patients was conducted from March 2020 to March 2024. Medical records of patients with acute SARS-CoV-2 infection and a confirmed history of T2DM were thoroughly reviewed. The study included 54 women (52.43%) and 49 men (47.57%). To study the inflammatory markers, two groups of patients were formed based on the main target indicator of glycemic control HbA1c. Group A (HbA1c < 7.0%) included 33 patients (32.04%), while Group B (HbA1c ≥ 7.0%) included 70 patients (67.96%).

Results and discussion. Blood glucose levels were significantly higher in the group of patients with poorly controlled diabetes compared to the group with well-controlled diabetes – 10.8 [8.55–14.4] vs. 7.0 [5.9–9.3] (p < 0.001). In Group A, the median HbA1c level was significantly lower than in Group B, which is expected: 6.27 [6.08–6.63] vs. 8.55 [7.79–10.1] (p < 0.001). Patients with poorly controlled diabetes showed significantly higher C-reactive protein levels 95.1 [60.5–174] vs. 61.4 [14.7–138] (p = 0,021), more pronounced among women; neutrophilia 9.69 [6.48–14.5] vs. 6.1 [3.56–10.3] (p = 0,005); neutrophil-to-lymphocyte ratio 5.74 [3.17–9.97] vs. 4.22 [1.94–9.11] (p = 0,163). A direct correlation was observed between inflammatory markers interleukin-6 and ferritin in patients with poorly controlled diabetes and elevated HbA1c levels.

Conclusions. In patients with poorly controlled diabetes, significantly higher levels of C-RP and pronounced neutrophilia were observed. A direct correlation was found between inflammatory markers IL-6 and ferritin and elevated HbA1c levels in the group of patients with poorly controlled diabetes, confirming the link between chronic hyperglycemia and systemic inflammation.

Keywords: type 2 diabetes mellitus, coronavirus infection, COVID-19, inflammatory markers, glycemic control.

REFERENCES

  1. IDF Diabetes Atlas. 11th edition. 2025. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/.
  2. Ministry of Health of Ukraine, 2023. Half a million Ukrainians were diagnosed with diabetes in 2023. Available at: https://moz.gov.ua/uk/u-piv-miljona-ukrainciv-diagnostovano-cukrovij-diabet-u-2023-roci (accessed July 11, 2024).
  3. Panina SS, Hondulenko NO, Sanina NA, et al. Prevention and ways to reduce disability due to diabetes. Ukrainian Bulletin of Medical and Social Expertise. 2018;3–4(29–30):23–29 (In Ukrainian). Available at: http://nbuv.gov.ua/UJRN/ ujmse_2018_3-4_7.
  4. Nevska AO, Pohosian OA, Goncharuk KO, et al. Detecting diabetic retinopathy using an artificial intelligence-based software platform: a pilot study. Ophthalmol. (Ukraine). 2024;(1):27–31. https://ua.ozhurnal.com/index.php/files/article/ view/101.
  5. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes and Metabolic Syndrome: Clinical Research Reviews. 2020;14(6):2245–2249. DOI: 10.1016/j.dsx.2020.11.007.
  6. Jiang G, Luk AO, Tam CHT, et al. Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. PLOS Medicine. 2020;17(7):e1003209. DOI: 10.1371/journal.pmed.1003209.
  7. Zhu L, She Z-G, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Preexisting Type 2 Diabetes. Cell Metab. 2020;31:1068–77. DOI: 10.1016/j.cmet.2020.04.021.
  8. Craciun L, Ignuta F, Rayudu US, et al. Тhe Role of Glycemic Control in Inflammation Markers and Clinical Outcomes in Type 2 Diabetes Patients with Severe COVID-19. Biomedicines. 2025; 13(4):886. DOI: 10.3390/biomedicines13040886.
  9. Son NE. Influence of ferritin levels and inflammatory markers on HbA1c in the Type 2 Diabetes mellitus patients. Pak J Med Sci. 2019;35(4):1030–1035. DOI: 10.12669/pjms.35.4.1003.
  10. Elimam H, Abdulla AM, Taha IM. Inflammatory markers and control of type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(1):800–804. DOI: 10.1016/j.dsx.2018.11.061.
  11. Halim C, Mirza A F, Sari MI. The association between TNF-α, IL-6, and vitamin D levels and COVID-19 severity and mortality: a systematic review and meta-analysis. Pathogens. 2022;11(2):195. DOI: 10.3390/pathogens11020195.
  12. Lytvyn KYu, Bilokon OO. Factors associated with variability in il-6 levels in patients with Covid-19. Infectious Diseases. 2023;2:9–14. DOI: 10.11603/1681-2727.2023.2.14097.
  13. Pushkarev V, Levchuk N, Sokolova L, Pushkarev V, Kovzun O, Tronko M. Bradykinin and interleukin-6 content in the blood of patients with COVID-19 and diabetes mellitus. Endokrynologia. 2024;29(3):201–206. DOI: 10.31793/1680-1466. 2024.29-3.201,
  14. Reddy V, Shiddapur G, Jagdale N, et al. Investigating Interleukin-6 Levels in Type 2 Diabetes Mellitus Patients with and Without Diabetic Nephropathy. Cureus. 2024; 16(8): e67014. doi:10.7759/cureus.67014.
  15. Rasputniak OV, Gavrilenko TI, Pidgaina OA, Trembovetska OM, Lomakovskyi OM, Shnaider LM. Cardiovascular Complications of COVID-19: Review of Cardiac Injury Pathophysiology and Clinical Evidence. Ukrainian Journal of Cardiovascular Surgery. 2024;32(2):92–104. DOI: 10.30702/ujcvs/24.32(02)/RG021-92104.
  16. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation Pathobiology. 2021;88(1):15–27. DOI: 10.1159/000512007.
  17. Furmanova OV, Zak KP, Popova VV, Tronko MD. Blood leukocyte composition and neutrophil to lymphocyte ratio in patients with newly diagnosed type 2 diabetes mellitus depending on the degree of overweight/obesity. Іnternational Journal of Еndocrinology (Ukraine). 2020;16(7):526–533. DOI: 10.22141/2224-0721.16.7.2020.219006.
  18. Zhang J, Ma Y, To WL, et al. Impact of COVID-19 infection on mortality, diabetic complications and haematological parameters in patients with diabetes mellitus: a systematic review and meta-analysis. BMJ Open. 2025;15:e090986. DOI: 10.1136/ bmjopen-2024-090986.
  19. Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2017;11(1):S127–31. DOI: 10.1016/j.dsx.2016.12.021.
  20. Varma S, Khande M, Gupta P, et al. Correlation of neutrophil lymphocyte ratio with HbA1c in patients of type 2 diabetes mellitus. Int J Adv Med. 2021;8:952–6. DOI: 10.18203/2349-3933.ijam20212407.
  21. Lin S, Mao W, Zou Q, Lu S, Zheng S. Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection. J Clin Lab Anal. 2021;35(1):e23604. DOI: 10.1002/jcla.23604.
View article PDF